N
Nobuhiko Seki
Researcher at Teikyo University
Publications - 105
Citations - 1768
Nobuhiko Seki is an academic researcher from Teikyo University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 19, co-authored 90 publications receiving 1470 citations. Previous affiliations of Nobuhiko Seki include Kindai University & Tokai University.
Papers
More filters
Journal ArticleDOI
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Shigeaki Suzuki,Nobuhisa Ishikawa,Fumie Konoeda,Nobuhiko Seki,Satoshi Fukushima,Kikuko Takahashi,Hisashi Uhara,Yoshikazu Hasegawa,Shinichiro Inomata,Yasushi Otani,Kenji Yokota,T. Hirose,Ryo Tanaka,Norihiro Suzuki,Makoto Matsui +14 more
TL;DR: The prompt and correct recognition of MG following treatment with immune checkpoint inhibitors in patients with cancer is important and postintervention status showed that pharmacologic remission or minimal manifestations were obtained in 4 patients; however, 2 patients died.
Journal ArticleDOI
Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301
Sayaka Onoda,Noriyuki Masuda,Takashi Seto,Kenji Eguchi,Yuichi Takiguchi,Hiroshi Isobe,Hiroaki Okamoto,Takashi Ogura,Akira Yokoyama,Nobuhiko Seki,Yoshiko Asaka-Amano,Masao Harada,Akihiro Tagawa,Hiroshi Kunikane,Masanori Yokoba,Kazutsugu Uematsu,Takayuki Kuriyama,Yumi Kuroiwa,Koshiro Watanabe +18 more
TL;DR: Amrubicin exhibits significant activity against SCLC, with predictable and manageable toxicities; this agent deserves to be studied more extensively in additional trials.
Journal ArticleDOI
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Kentaro Yamazaki,Michitaka Nagase,Hiroshi Tamagawa,Shinya Ueda,Takao Tamura,Kohei Murata,T. Eguchi Nakajima,Eishi Baba,Miho Tsuda,Toshikazu Moriwaki,Taito Esaki,Yasushi Tsuji,K. Muro,Koichi Taira,Tadamichi Denda,Sadao Funai,K. Shinozaki,Hideaki Yamashita,Naotoshi Sugimoto,Tatsuya Okuno,Tomohiro Nishina,M. Umeki,T. Kurimoto,Tetsuji Takayama,Akihito Tsuji,Motoki Yoshida,Ayumu Hosokawa,Yoshihiro Shibata,Koichi Suyama,Masataka Okabe,Kenji Suzuki,Nobuhiko Seki,Kentaro Kawakami,Michihiko Sato,Koshi Fujikawa,Tomonori Hirashima,Takaya Shimura,Keisei Taku,Toshio Otsuji,F. Tamura,Eiji Shinozaki,K. Nakashima,Hiroki Hara,Takahiro Tsushima,M. Ando,Satoshi Morita,Narikazu Boku,Ichinosuke Hyodo +47 more
TL;DR: FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus beVacIZumab, as the first-line systemic treatment for mCRC.
Journal ArticleDOI
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Takashi Seto,Masahiko Higashiyama,Hiroko Funai,Fumio Imamura,Kazutsugu Uematsu,Nobuhiko Seki,Kenji Eguchi,Takeharu Yamanaka,Yukito Ichinose +8 more
TL;DR: In this article, the prognostic value of the expression of vascular endothelial growth factor (VEGF) and of the VEGF receptors (VEGFRs) fms-like tyrosine kinase receptor-1 (flt-1) and kinase insert domain-containing receptor (KDR) in non-small-cell lung cancer (NSCLC) was examined.
Journal Article
Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung.
Nobuhiko Seki,Tasaburo Takasu,Koichi Mandai,Masao Nakata,Hideyuki Saeki,Yuji Heike,Ichiro Takata,Yoshihiko Segawa,Toshiaki Hanafusa,Kenji Eguchi +9 more
TL;DR: The results suggest that translational control is dysregulated during the development of peripheral lung adenocarcinoma and that progressive increases of tumoral and stromal eIF4E may be part of a positive feedback loop for malignant progression.